Genialis and Inventia Partnered on Cancer Research
The companies have joined forces to create human-relevant 3D models for testing pancreatic cancer treatments.
Updated on Sept. 23, 2026 in Cancer
Live Poll
Should medical researchers prioritize using patient-derived human cell models to test new cancer treatments?
Genialis and Inventia Life Sciences have launched a collaboration to link AI-driven patient biology with 3D pancreatic cancer models. The project seeks to improve drug testing and patient matching for pancreatic ductal adenocarcinoma.
Why it matters
This partnership aims to bridge the gap between clinical tumor microenvironment data and laboratory testing models. By creating more accurate representations of human disease, researchers hope to better predict how new cancer treatments will perform in patients.
Researchers analyzed 644 tumor profiles from the PanCAN SPARK cohort to inform model development. The study characterizes 3D models by connecting them to molecular states identified in clinical settings.
The players
Genialis
Genialis is a biopharmaceutical software company that specializes in AI-powered data integration to better understand patient biology.
Inventia Life Sciences
Inventia Life Sciences is a biotechnology firm that develops advanced 3D cell-based models for drug discovery and medical research.
PanCAN
The Pancreatic Cancer Action Network is a non-profit organization focused on providing patient support and funding scientific research.
The details
The collaboration integrates the Genialis AI Supermodel with the RASTRUM 3D cell model platform developed by Inventia Life Sciences. Scientists mapped patient profiles to tumor-fibroblast co-culture models, focusing on patients identified with poor prognoses based on tumor microenvironment activity.
Timeline
September 23, 2026: The partnership was announced.
September 25, 2026: Researchers will present initial study findings at the PanCAN Scientific Summit in San Diego.
The Big Picture
This collaboration utilizes the PanCAN SPARK cohort to standardize the development of preclinical testing tools. It follows a growing trend in oncology to utilize large-scale clinical datasets for the validation of experimental 3D modeling technologies.
While this research is in the preclinical stage, it directly impacts the future of pancreatic cancer care by aiming to increase the accuracy of treatment matching. These models may eventually reduce the time and failure rates associated with identifying effective therapies for patients with poor prognoses.
The takeaway
This development highlights the shift toward using artificial intelligence to bridge the gap between static patient data and dynamic laboratory experiments. Such innovations are critical for translating complex molecular profiles into more personalized cancer treatment strategies.
Further reading
For more on the current state of oncology research and new therapeutic approaches, visit the Cancer section.
Source note: This article includes information reported by GEN - Genetic Engineering and Biotechnology News.
Live Poll
Should medical researchers prioritize using patient-derived human cell models to test new cancer treatments?
